This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
OncoMed closes $154mm Series B round; later adds on $15mm
30 Oct 2017
OncoMed Pharmaceuticals (anticancer stem cell antibodies) has raised $93mm through the second and final closing of its Series B round, bringing the total amount to $154mm. New investor Nomura Phase4 Ventures participated, along with returning buyers US Venture Partners, Latterell Venture Partners, the Vertical Group, Morgenthaler Ventures, Adams Street Partners, De Novo Ventures, Bay Partners, and development partner GlaxoSmithKline. Nomura Phase4's managing director will join OncoMed's board.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?